An EGFR/HER2 dual-targeted inhibitor called pyrotinib has exhibited stronger tumor-suppressive effects in advanced LUAD patients carrying HER2 exon 20 mutations,74 closely related to its comprehensive inhibition of the HER2 signaling pathway. This evidence concerns the gene ERBB2 and neoplasm.